NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...

New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...

WVU Cancer Institute became the first in the world to treat ultra-rare, aggressive CD19-positive MPAL with subcutaneous ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

For decades, complex infused therapies were anchored to hospitals. Higher acuity was assumed to require inpatient walls, and infusion centers were viewed primarily as transitional sites rather than ...

Cancer treatments must now go beyond the usual concerns of patients who grapple with their high costs in favor of improving quality of life, according to ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...